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ABSTRACT
Objective: The single nucleotide polymorphism C677T of the methylenetetrahydrofolate reductase (MTHFR) gene encodes a thermolabile enzyme. 
This polymorphism was found to be implicated in cancer susceptibility. In this study, we analyzed the distribution of the MTHFR C677T polymorphism 
in two cohorts; patients and controls native of East of Algeria to explore the possible association between this polymorphism and prostate cancer 
susceptibility.
Methods: Our examination has been conducted in 98 cases and 98 healthy controls. Genotyping was realized by polymerase chain reaction-restriction 
fragment length polymorphism method.
Results: Compared with CC homozygous, the CT heterozygous was found to have a significantly increased risk of prostate cancer (p=0.04; odds ratio 
[OR]=2.01, 95% confidence interval [CI]: 1.02–3.95). However, no statistically significant difference was observed concerning the TT homozygous 
(p=0.74; OR=1.25, 95% CI: 0.51–3.04).
Conclusion: Our results indicate that the genotype CT is a risk factor for prostate cancer in East of Algeria.
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INTRODUCTION
Prostate cancer is one of the most common malignant cancer in 
terms of prevalence and the second leading cause of death among 
men [1-3]. The methylenetetrahydrofolate reductase (MTHFR) is 
a key enzyme in the metabolism of folates, which are crucial for 
deoxyribonucleic acid (DNA) methylation, nucleotide synthesis, 
and genomic integrity [4]. The MTHFR catalyzes an irreversible 
conversion of the substrate 5,10-methylenetetrahydrofolate (CH2-H4 
folate) to 5-methyltetrahydrofolate (CH3-H4 folate) [5,6]. The 5,10-
MTHF ensures the synthesis of deoxythymidylate monophosphate 
(dTMP) from deoxyuridylate monophosphate (dUMP). The increases 
of dTMP in the nucleotide provisions underrate the misincorporation 
of the dUMP in DNA sequence, so it decreases double-strand breaks. 
The 5-MTHF ensures methylation of the amino acid homocysteine 
to methionine, a reaction by which, the universal donor of the one-
carbon group is synthesized, the S-adenosyl methionine (SAM), 
essential for methylation reactions [6,7]. DNA methylation profile 
change could cause oncogene activation and genomic instability 
after hypomethylation or influence on tumor suppressor genes 
following hypermethylation and silences their expression, which can 
provide prostate tumor development [6,8,9]. The variant MTHFR 
C677T leads to the substitution of alanine to valine, which generates 
a thermolabile enzyme, with approximately 35 % of the reduction in 
activity in heterozygous, and 70% in homozygous [10,11]. The MTHFR 
C677T polymorphism has been related to many cancers such as acute 
lymphoblastic leukemia of adult [12], the digestive system [13,14], 
differentiated thyroid carcinoma [15], breast cancer [16], and prostate 
cancer [17]. The aim of this study was to examine the relationship 
between the MTHFR C677T polymorphism and prostate cancer risk in 
the East Algerian population.
METHODS
Subjects of study
We conducted a case–control study for this purpose we recruited 98 
prostate cancer cases and 98 controls. All patients were histologically 
diagnosed with prostate cancer; thus, all stages of this tumor 
development have been included [18] blood samples were collected 
at the Uro-Nephrology Hospital “the Department of Urology and 
Renal Transplantation,” Constantine, Algeria. Control subjects were 
volunteers, healthy men, without a family history of prostate cancer 
and they were free of cancer at the time of blood-sample. Patients and 
controls are native to different regions of East of Algeria. Prostate cancer 
case and healthy control were matched by age (±5 years). Our research 
has been approved by the local Ethics Committee. All participants gave 
their written informed consent for approximately 7 ml peripheral blood 
sample, after the interview.
Genotyping
Genomic DNA was extracted from leukocytes, using salting out 
procedure [19]. MTHFR genotyping was performed for the single 
nucleotide polymorphism (SNP) C677T by polymerase chain reaction 
(PCR)-restriction fragment length polymorphism (RFLP). The primer 
sequences used were Forward: 5’-TGAAGGAGAAGGTGTCTGCGGGA-3’ 
and Reverse: 5’-AGGACGGTGCGGTGAGAGTG-3’. PCR conditions were: 
Initial denaturation cycle at 94 °C for 5 min, 30 cycles, each cycle 
contains three stages: Denaturation at 94°C for 30 s, hybridization at 
65°C for 30 s, and elongation at 72°C for 40 s, and finally a terminal 
elongation at 72°C for 10 min. 30 µl of PCR product was digested with 
restriction enzyme HinfI (Promega, Madison, WI) at 37°C overnight, 
and digested products were separated on 3% Agarose gel. After that, 
fragments were visualized using ultra-violet light.
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Statistical analysis
Using Epi Info Version 6, differences in allelic and genotypic frequencies 
have been tested. *p˂0.05 was considered statistically significant.
RESULTS
In our study, patients and controls were aged between 49 and 89 years, 
with an average age of 70.33±7.65 years. General characteristics of the 
study population represented by; the age of the two cohorts distributed 
every 10 years, tumor extension, Prostate Specific Antigen (PSA)  levels 
at the time of diagnosis and the existence of a family history of prostate 
cancer have been shown in Table 1.
Almost all patients have been diagnosed at age 60 and more. Also, 
62.24 % of them at late stage and distant metastasis. Furthermore, 
58.16 % of patients with PSA levels above 50 ng/ml, underlining 
delayed diagnosis.
DNA fragments obtained after digestion by the restriction enzyme HinfI 
and electrophoresis were TT, mutant homozygote (one band of 175 
base pairs [bp]); CT, heterozygote (two bands of 198 bp and 175 bp); 
CC, wild-type homozygote (one band of 198 bp).
Distribution of allelic and genotypic frequencies for the polymorphism 
MTHFR C677T between prostate cancer patients and controls and their 
relation with risk of prostatic carcinogenesis is presented in Table 2.
Our results showed that the 677 CT genotype was frequent between 
cases (p=0.04), (odds ratio [OR]: 2.01, confidence interval [CI]: 1.02–
3.95), suggesting that they may be a risk factor for prostate cancer. On 
the other hand, for the 677 TT genotype, any statistically significant 
difference between cases and controls was observed (p=0.74), (OR: 
1.25, CI: 0.51–3.04). Concerning the T allele frequency of the C677T 
SNP was 0.41 for patients and 0.36 for controls.
DISCUSSION
This paper reports for the first time in Algeria the relation between the 
MTHFR C677T polymorphism and susceptibility to developing prostatic 
cancer. Our results showed that there was an association between the 
MTHFR 677CT heterozygous and prostate cancer. In agreement with our 
results, Van Guelpen et al. [7], Marchal et al. [20], López-Cortés et al. [17], 
and Abedinzadeh et al. [21] reported a positive association between 
the polymorphism C677T and risk of prostatic cancer in the Swedish 
population, Spanish population, Ecuadorian, and Asians, respectively.
The significant association between the CT genotype and risk of 
prostate cancer may be explained by the possibility to keep a sufficient 
stock of methionine to support neoplastic clone progression compared 
with the TT homozygous [20].
However, various investigations have not found any relation between 
this polymorphism and prostate cancer in Caucasians population [4], 
the Swedish population [6], and Americans [22]. As well, the meta-
analysis managed by Collin et al. [23], Zhang et al. [24], and recently, 
Abedinzadeh et al. [21] has concluded that the C677T polymorphism, in 
general, has no effect on the occurrence of prostate cancer.
Besides, other authors observed that the T allele exerts a protective 
impact on prostate cancer risk. Like they indicated Marchal et al. [20], 
and Guo et al. [25] that the genotype 677 TT is a protective factor in 
Spanish and Asians, respectively. As well, Cai et al. [26] showed that the 
TT genotype has been associated with a reduced risk of prostate cancer 
in the Chinese population, and the T allele exerts probably a protective 
effect on the risk of this cancer type. Furthermore, Li and Xu [27], who 
had carried out a meta-analysis, have reported the same result for the 
T allele. Safarinejad et al. [28] have studied the association between 
tumoral aggressiveness and TT, CT, and CC genotypes: The comparison 
showed that TT homozygous reduced by more than 50% the risk of 
high-grade prostate cancer (Gleason score >7).
In addition, Küçükhüseyin et al. [29] proposed that the CT genotype and 
the T allele might be associated with decreased risk of prostate cancer 
among the Turks. Singal et al. [30] suggested that the CT genotype was 
associated with a reduced risk of prostate cancer.
To explain the protective effect of the T allele on prostate cancer, it 
has been proposed that the mutant 677 TT genotype was associated 
with significantly decreased DNA methylation status. The reduced 
activity of MTHFR enzyme, coded by the T allele, decreases the 
SAM synthesis, the headmaster donor of a methyl group for DNA 
methylation reactions, favor thereby tumor suppressor genes 
expression [20]. Second, the thermolabile enzyme increases the 
pool of the 5,10-methylenetetrahydrofolate, requisite for purine 
and deoxythymidylate triphosphate synthesis, which is the leader 
nucleotide, required for DNA reparation, consequently, a decrease 
of uracil incorporation inside DNA, reduce thereby chromosome 
breaks [20,31]. Furthermore, in vitro experiences approve that 
inhibition of MTHFR enzyme conduct to decreasing tumor development 
due to the limited methionine provision, which leads to stop the cell 
cycle on steps S and G2, damage thus their proliferative potential [20].
The contradictory results from studies of different populations may 
be explained by the method by which controls have been selected, the 
ethnic origin of cases and controls, geographical region, lifestyle and 
exposition to some factors [32,33].
CONCLUSION
The results suggest for the first time, but in a small sample of subjects, 
that the 677 CT heterozygous is a risk factor for prostatic carcinogenesis. 
Further researches should be undertaken that includes other possible 
genes that participate in the homocysteine metabolism, such as 






50–59 3 (3.06) 13 (13.26)
60–69 33 (33.67) 39 (39.79)
≥70 62 (63.26) 46 (46.93)
Early stage (T1, T2) 37 (37.75) -
Late stage and distant metastasis 61 (62.24) -
PSA level at diagnosis (ng/ml)
˂4 3 (3.06) -
4–10 9 (9.18) -
10–50 29 (29.59) -
≥50 57 (58.16) -
Family history
Yes 21 (21.42) -
No 77 (78.57) -
n: Number. PSA: Prostate specific antigen
Table 2: Distribution of allelic and genotypic frequencies for 
the polymorphism MTHFR C677T between prostate cancer 














CC 32 (32.65) 45 (45.92) - -
CT 50 (51.02) 35 (35.71) 2.01 (1.02–3.95) 0.04
TT 16 (16.32) 18 (18.37) 1.25 (0.51–3.04) 0.74
CT or TT 66 (67.35) 53 (54.08) 1.75 (0.94–3.26) 0.07
C allele 114 (58.16) 125 (63.77) - -
T allele 82 (41.84) 71 (36.22) 1.62 (0.90–2.94) 0.11
n: Number, OR: Odds ratio, CI: Confidence interval. 
MTHFR: Methylenetetrahydrofolate reductase
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methionine synthase. The influence of the environment, the gene-gene 
as well as gene-environment interactions should also be performed to 
clarify their possible roles in prostatic carcinogenesis.
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